SEC Form 4 · accession 0001209191-18-054544
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Reshma Kewalramani
Officer — EVP and CMO
Period of report
Oct 8, 2018
Accepted (ET)
Oct 9, 2018 · 4:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 8, 2018 | S | 2,305 | $186.95 | D | 1,909 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Dr. Kewalramani's company-approved trading plan under Rule 10b5-1.